Optimizing treatment with risperidone long - acting injections

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F65269705%3A_____%2F12%3A%230001768" target="_blank" >RIV/65269705:_____/12:#0001768 - isvavai.cz</a>
Alternative codes found
RIV/00216224:14740/12:00062126
Result on the web
<a href="http://dx.doi.org/10.1111/acps.12014" target="_blank" >http://dx.doi.org/10.1111/acps.12014</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1111/acps.12014" target="_blank" >10.1111/acps.12014</a>

Result language
angličtina
Original language name
Optimizing treatment with risperidone long - acting injections
Original language description
The outcome could be improved by targeting RLAI treatment at specific patient groups and optimizing the dose. RLAI should be quickly titrated to an effective dose in patients known to be responsive to antipsychotic treatment. The high frequency of co medication in our sample indicates a certain level of pharmacoresistance. In spite of this, a significant decrease in concomitant medication was observed. Therapeutic drug monitoring is another possibility for optimizing treatment with RLAI.
Czech name
—
Czech description
—

Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FL - Psychiatry, sexology
OECD FORD branch
—

Project
<a href="/en/project/ED1.1.00%2F02.0068" target="_blank" >ED1.1.00/02.0068: Central european institute of technology</a><br>
Continuities
V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Publication year
2012
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)